Flupenthixol Decanoate in Methamphetamine Smoking - 1

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Friends Research Institute, Inc.
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000241

Purpose

The purpose of this study is to evaluate the safety and efficacy of flupenthixol decanoate for treatment of methamphetamine dependence. Also, study will compare flupenthixol with desipramine in blocking methamphetamine self-administration.

Condition	Intervention	Phase
Substance-Related Disorders	Drug: Flupenthixol	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Flupenthixol Decanoate in Methamphetamine Smoking

Resource links provided by NLM:

MedlinePlus related topics: Methamphetamine Smoking

Drug Information available for: Methamphetamine hydrochloride Flupenthixol decanoate Amphetamine Methamphetamine Flupenthixol

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Methamphetamine use

Estimated Enrollment:	58
Study Start Date:	February 1994
Estimated Study Completion Date:	May 1996

Eligibility

Ages Eligible for Study:	22 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000241

Locations

United States, California
Friends Research Institute
Los Angeles, California, United States, 90025

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Friends Research Institute, Inc.

Investigators

Principal Investigator:

Frank Gawin, M.D.

Friends Research Institute, Inc.

More Information

No publications provided

Study ID Numbers:	NIDA-07200-1, R01-07200-1
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000241 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Dopamine Uptake Inhibitors
Flupenthixol
Neurotransmitter Agents
Tranquilizing Agents
Adrenergic Agents
Flupenthixol decanoate
Psychotropic Drugs
Central Nervous System Depressants
Disorders of Environmental Origin
Central Nervous System Stimulants

Antipsychotic Agents
Smoking
Methamphetamine
Dopamine
Mental Disorders
Substance-Related Disorders
Amphetamine
Dopamine Agents
Peripheral Nervous System Agents

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Flupenthixol decanoate
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Psychotropic Drugs
Disorders of Environmental Origin
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Flupenthixol

Tranquilizing Agents
Sympathomimetics
Central Nervous System Depressants
Dopamine Antagonists
Central Nervous System Stimulants
Antipsychotic Agents
Pharmacologic Actions
Methamphetamine
Autonomic Agents
Dopamine Agents
Amphetamine
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on July 02, 2009